Authors

Latest:

Dr. Kondziolka on Therapy for Patients With Melanoma Who Have Brain Mets

Doug Kondziolka, MD, professor and vice chair of Clinical Research, NYU Langone Medical Center, discusses therapeutic approaches for patients with melanoma who have brain metastases.

Doug Moeller, MD

Latest:

Unlocked Genomes Provide Clinical Answers, But Questions About Universal Test Catalog Remain

Although we've known for decades that heredity is a major factor in cancer susceptibility and management, the insights gained in the past decade are still breathtaking.

Douglas A. Levine, MD

Latest:

Dr. Levine Discusses a Combination Study in Endometrial Cancer

Douglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, director, Division of Gynecologic Oncology, NYU Langone's Perlmutter Cancer Center, discusses the randomized NRG Oncology Group 86P study for patients with endometrial cancer.

Douglas A. Nelson, MD

Latest:

Dr. Nelson on the Future Utility of ctDNA in CRC

Douglas A. Nelson, MD, discusses the future utility of circulating tumor DNA in colorectal cancer.

Douglas B. Chepeha, MD

Latest:

Parotid Node Metastases in Locally Advanced Nasopharyngeal and Oropharyngeal Cancer: Implications for Radiotherapy Target Volume Delineation

The ipsilateral parotidean nodes may be at risk of metastatic involvement when bulky ipsilateral level II metastases and multilevel nodal disease are co-existent, possibly due to retrograde lymphatic drainage.

Douglas B. Evans, MD, FACS

Latest:

Dr. Douglas Evans on Neadjuvant Therapy for Pancreas Cancer

Douglas B. Evans, MD, FACS, Chair, Professor, Donald C. Ausman Family Foundation Professor of Surgery, Medical College of Wisconsin, discusses how to appropriately sequence therapies for pancreatic cancer.

Douglas B. Johnson, MD

Latest:

Dr. Johnson on the Rationale for Examining Chronic irAEs Associated With Anti-PD-1 Therapy in Melanoma

Douglas B. Johnson, MD, discusses the rationale for examining chronic immune-related adverse effects associated with anti–PD-1 therapy in patients with high-risk resected melanoma.

Douglas K. Marks, MD

Latest:

Dr. Marks on Investigational Antibody-Drug Conjugates in HER2+ Breast Cancer

Douglas K. Marks, MD, discusses investigational antibody–drug conjugates in HER2-positive breast cancer.

Douglas Kondziolka, MD

Latest:

Dr. Kondziolka Discusses Updates in the Treatment of Brain Metastases

Douglas Kondziolka, MD, MSc, director, Gamma Knife Program, vice chair, Clinical Research, Departments of Neurosurgery and Radiation Oncology, Perlmutter Cancer Center at NYU Langone, discusses updates concerning the treatment of brain metastases.

Douglas Letson MD

Latest:

Phase II Clinical Trial of Intratumoral Dendritic Cells Injections and Neoadjuvant Radiotherapy in Resectable Soft Tissue Sarcomas

Neoadjuvant radiation with dendritic cell injections has the potential to be safe, effective, and immunogenic in high-grade soft tissue sarcoma and needs to be confirmed in randomized larger clinical trials.

Douglas Moeller, MD

Latest:

Z-Code Identifiers Give Providers Objective Information About Molecular Tests

Virtually everyone in the clinical laboratory business is now acquainted with Z-code identifiers. Each unique laboratory test should have a unique tracking code, even if more than one Z-code identifier is reported with a corresponding American Medical Association's Current Procedural Terminology (CPT) billing code.

Douglas R. Lowy, MD

Latest:

Dr. Doug Lowy on Preventing Cancer Through Vaccination

Douglas R. Lowy, MD, acting director, National Cancer Institute, chief, Laboratory of Cellular Oncology, senior Investigator, Head, Signaling and Oncogenesis Section, discusses vaccines that may show efficacy in certain tumor types.

Douglas Yee, MD

Latest:

Dr Yee on Neoadjuvant Datopotamab Deruxtecan Plus Durvalumab in Early-Stage Breast Cancer

Douglas Yee, MD, discusses datopotamab deruxtecan and durvalumab in the neoadjuvant setting for early-stage breast cancer.

Dr. Adam Bass

Latest:

Dr. Adam Bass on the Origins of Different Gastric Tumor Types

Dr. Adam Bass, MD, Dana-Farber Cancer Institute, discusses the causes for different types of gastric cancer.

Dr. George Somlo, MD

Latest:

Dr. George Somlo on Advances in Multiple Myeloma

Dr. George Somlo, MD, medical oncologist, City of Hope, discusses recent highlights in multiple myeloma.

Dr. Hisham Mehanna

Latest:

Dr. Hisham Mehanna on Quality of Life Differences in Head and Neck Squamous Cell Cancer

Hisham Mehanna, MBChB, PhD, Chair, Head and Neck Surgery, Director, Institute of Head and Neck Studies and Education at University of Birmingham, discusses differences in the quality of life (QoL) and functional outcomes of treatment between HPV-positive and HPV-negative head and neck squamous cell cancer patients (HNSCC).

Dr. Jordi Bruix, MD

Latest:

Dr. Jordi Bruix on the Impact Regorafenib Will Have on Liver Cancer Treatment

Dr. Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer (BCLC) at University of Barcelona, discusses the major impact that regorafenib (Stivarga) will have for the treatment of hepatocellular carcinoma (HCC).

Dr. Navesh K. Sharma

Latest:

Dr. Navesh K. Sharma on Older Patients Tolerating Internal Radiation

Dr. Navesh K. Sharma, associate professor of Radiology in the Division of Radiology and Oncology at Penn State Hershey Medical Center and section chief of Radiation Oncology at the Penn State Health St. Joseph Cancer Center, discusses that age should not be a deciding factor in giving internal radiation to patients with liver cancer.

Dr. Peter Kufer, Vice President & Innovator of BITE Technology, Amgen Sponsored by Amgen Oncology

Latest:

BiTE Platform and the Evolution Toward Off-The-Shelf Immuno-Oncology Approaches

Amgen Oncology is committed to investigating innovative approaches to fighting cancer, across both hematological malignancies and solid tumors.

Dr. Volker Heinemann, MD, PhD

Latest:

Dr. Volker Heinemann on the Addition of SIRT to Chemotherapy for mCRC

Volker Heinemann, MD, PhD, director of the Comprehensive Cancer Center at Ludwig Maximilian University of Munich, discusses how depth of response, which is highly correlated with overall survival, was improved for patients with metastatic colorectal cancer who added selective internal radiation therapy (SIRT) to chemotherapy.